BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Demény MA, Virág L. The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions. Cancers (Basel) 2021;13:2057. [PMID: 33923319 DOI: 10.3390/cancers13092057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Peng X, Pan W, Jiang F, Chen W, Qi Z, Peng W, Chen J. Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106529] [Reference Citation Analysis]
2 Xie T, Dickson K, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers 2022;14:4621. [DOI: 10.3390/cancers14194621] [Reference Citation Analysis]
3 Xiong J, Barayan R, Louie AV, Lok BH. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. Semin Cancer Biol 2022:S1044-579X(22)00179-1. [PMID: 35917883 DOI: 10.1016/j.semcancer.2022.07.008] [Reference Citation Analysis]
4 Nagy-pénzes M, Hajnády Z, Regdon Z, Demény MÁ, Kovács K, El-hamoly T, Maléth J, Hegyi P, Hegedűs C, Virág L. Tricetin Reduces Inflammation and Acinar Cell Injury in Cerulein-Induced Acute Pancreatitis: The Role of Oxidative Stress-Induced DNA Damage Signaling. Biomedicines 2022;10:1371. [DOI: 10.3390/biomedicines10061371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Muoio D, Laspata N, Fouquerel E. Functions of ADP-ribose transferases in the maintenance of telomere integrity. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04235-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Quesada S, Fabbro M, Solassol J. Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers (Basel) 2022;14:1132. [PMID: 35267439 DOI: 10.3390/cancers14051132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Quesada S, Fabbro M, Solassol J. Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers (Basel) 2022;14:1098. [PMID: 35205846 DOI: 10.3390/cancers14041098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Wei X, Wu X, Cheng Z, Wu Q, Cao C, Xu X, Shang H. Botanical drugs: a new strategy for structure-based target prediction. Brief Bioinform 2021:bbab425. [PMID: 34698349 DOI: 10.1093/bib/bbab425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Demény MA, Virág L. The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks. Cancers (Basel) 2021;13:2042. [PMID: 33922595 DOI: 10.3390/cancers13092042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]